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A COMPARISON OF BLOOD VOLUME PULSE AND FALSE
BIOFEEDBACK IN THE TREATMENT OF MIGRAINE

Paul Greilick, Ph.D.
Western Michigan University, 1992

The efficacy of temporal artery blood volume pulse (BVP) biofeedback in the
treatment of migraine was investigated.

After four pre-treatment baseline

psychophysiological monitoring sessions, 8 migrainuers were randomly assigned to
undergo 12 sessions of either BVP biofeedback or a placebo procedure (false
feedback). Both treatments resulted in clinically significant and statistically equivalent
reductions in headache activity and medication intake. Subjects exhibited substantial
w ithin-session decreases in BVP amplitude during pre-treatment baseline sessions
and during false feedback, and the introduction of BVP biofeedback failed to increase
the magnitude or the rate of BVP amplitude reductions. All subjects failed to show
evidence of learned regulation of temporal artery BVP amplitude or BVP variability.
No significant correlations were found between degree of headache reduction and
amount of BVP amplitude reduction or amount of BVP variability.
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INTRODUCTION

Surveys have revealed that 20-25% of the general population suffer from
migraine headaches, and that 5-10% seek intermittent medical treatment for relief of
disabling headache (Bonica, 1990). As defined by the International Headache Society
(Olesen, 1988), migraine is a chronic disorder manifesting in attacks of 4 to 72 hours
duration and characterized by headache that is unilateral, pulsating, of moderate to
severe intensity, is associated with nausea or photo/phonophobia, and is aggravated
by physical exertion, is familial, and is related to the menstrual cycle. Migraine with
aura (classic migraine) is characterized by neurologic symptoms which precede
headache onset, and are unequivocally localized to the cerebral cortex or brain stem.
Migraine attacks are associated with a complex sequence of neurological, biochemical,
and vascular changes.

Experimental evidence has increasingly supported the

hypothesis that unstable serotonergic neurotransmission is an important mechanism
in migraine pathophysiology, and that vascular dysautoregulation and muscle
contraction are probably epiphenomenon (Raskin, 1988).
The vascular features of migraine have been the focus of extensive research
since Graham and Wolff (1938) demonstrated the simultaneous reduction of temporal
artery blood volume pulse amplitude and head pain following the administration of
ergotamine to patients with migraine headache. Vascular changes associated with
migraine headache were further detailed by Tunis and W olff (1953), who reported a
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four-stage sequence of change in cranial non-cerebral arteries (vasodilationvasoconstriction-lability-vasodilation) beginning four days preceding migraine
headache, a finding replicated by Feuerstein, Bortolussi, Houle, and Labbe (1983).
In addition to these extracranial vasomotor changes associated with migraine onset
and termination, some investigators have reported that migrainuers exhibit a number
of differences in temporal artery vasomotor activity compared to non-headache
controls, including greater beat-to-beat variability under baseline conditions (Morley,
1985), a greater number of abnormal pulse wave forms (Morley & Hunter, 1983),
greater dilation and constriction in response to stressors (Arena et al., 1985; Bakal &
Kaganov, 1976; Drummond, 1985; Morley, 1985; Rojahn & Gerhards, 1986), and
delayed return to baseline during post-stress adaptation (Arena et al., 1985; Gannon,
Haynes, Safranek, & Hamilton, 1981).
Citing potential clinical applications in the treatment of migraine headache,
successful bidirectional operant conditioning of cephalic vasomotor activity in non
headache subjects was first reported by Christie and Kotses (1973). Subsequently,
beginning with Koppman, McDonald, and Kunzel (1974), a number of investigators
reported blood volume pulse (BVP) amplitude biofeedback training to be effective in
the treatment of migraine (Allen & Mills, 1982; Bild & Adams, 1980; Elmore &
Tursky, 1981; Feuerstein & Adams, 1977; Friar & Beatty, 1976; Gauthier, Doyon,
Lacroix, & Drolet, 1983; Gauthier, Fournier, & Roberge, 1991; Gauthier, Fradet, &
Roberge, 1988;

Gauthier, Lacroix, Cote, Doyon, & Drolet, 1985; Knapp, 1982;

Lisspers & Ost, 1990; Sturgis, Tollison, & Adams, 1978). Although promising in
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terms of positive clinical outcome, the existing research on BVP biofeedback as a
treatment for migraine suffer from methodological limitations and from inadequate
evaluation of theoretical mechanisms.
The rationale for BVP biofeedback training in the treatment of migraine has
typically focused on the vascular changes associated with migraine originally reported
by Graham and Wolff (1938). Investigators have reasoned that if migrainuers can
learn voluntary regulation of temporal artery blood volume pulse amplitude and/or
variability, they can thereby produce and maintain vasomotor response patterns
incompatible with headache onset. However, attempts to correlate learned control of
BVP amplitude and/or variability with decreased headache in migrainuers have
yielded conflicting results. Thus, the mechanism by which BVP training works is
unclear.

Knapp (1982) suggested that the effectiveness of BVP biofeedback in

treating migraine is mediated through lowered sympathetic arousal via learned
generalized relaxation, which is consistent with the observation that temporal artery
pulse amplitude reduction is one aspect of a general decrease in sympathetic tonic
outflow (Dalessio, Kunzel, Stembach, & Sovak, 1979; Sovak, Kunzel, Stembach, &
Dalessio, 1978).
Two important methodological limitations in the BVP literature hamper
interpretation of the data. First, investigators have not adequately controlled for the
effects of adaptation of temporal vasomotor activity prior to initiating BVP
biofeedback, typically relying on a 5 to 10 minute baseline at the beginning of the
first and subsequent biofeedback session. Only one investigator brought subjects into
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the clinic for a fiill pretreatment monitoring session, during which subjects were
instructed to attempt to decrease their temporal artery blood flow without the aid of
feedback (Gauthier et al., 1985). She found that the majority of subjects (four of
seven) exhibited at least a 50% reduction in temporary artery BVP amplitude without
having been exposed to feedback, which raises the question of what the subjects
learned during subsequent biofeedback sessions. This also raises the question of the
role of adaptation in producing BVP amplitude decrements (within and/or across
sessions) which investigators have heretofore attributed to BVP biofeedback training.
A second methodological limitation is lack of adequate assessment and/or
control

of

movement-induced

BVP

signal

artifact,

to

which

reflectance

photoplethysmography is very susceptible (Flor & Turk, 1989). Investigators typically
instruct subjects to lie quietly and to avoid irregular respiration, and then rely on
visual rather than EMG monitoring of subjects to detect artifact inducing movement.
During pilot investigation for the present study, visual observation of the subject by
the experimenter was found to be unreliable in detecting systematic movement artifact.
Several subjects inadvertently learned to mediate control of the BVP signal via subtle
frontalis movements, which caused displacement of the BVP transducer which, in
turn, caused BVP signal attenuation.
The present study sought to replicate prior reports of clinical benefits of BVP
biofeedback training using a methodology that addressed some of the limitations of
prior research. In the present investigation, multiple physiological responses were
monitored over several pre- and post-treatment baseline sessions and, for half of the
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subjects, during extended placebo (false feedback) treatment.

This procedure

permitted both within-subject and group analyses to examine possible mechanisms
for changes in BVP activity and in headache activity. Specifically, the present study
was designed to answer the following questions:
1. Do migrainuers exhibit significantly greater temporal artery BVP amplitude
variability while at rest compared to non-headache controls?
2. Can adaptation account for reductions in BVP amplitude observed during
biofeedback training?
3. Is BVP biofeedback superior to an equally credible placebo (false feedback)
in reducing headache activity?
4. Is decreased headache activity correlated with learned voluntary control of
BVP amplitude or variability?
5. Are decreases in BVP amplitude correlated with lowered autonomic arousal
(heart rate)?
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METHOD

Subjects

Headache Subjects

Subjects were recruited from the community via newspaper advertisements
requesting volunteers to participate in a biofeedback treatment study for migraine. Of
the 19 initial respondents, the first 8 individuals who met inclusion criteria and agreed
to participate were selected (of the initial respondents, 4 did not meet inclusion
criteria and 7 chose not to participate). Inclusion criteria were consistent with that
typically required in similar investigations (e.g., Gauthier et al., 1985). Subjects had
to report an average of three migraines monthly for a minimum of two years, have
received a medical evaluation and diagnosis of migraine by a neurologist within the
past year, and meet three of the following criteria:

(a) unilateral and throbbing

headaches, (b) nausea and vomiting accompanying headaches, (c) headaches preceded
by prodromes, (d) photophobia during headaches, and (e) positive family history of
migraine. Subjects were excluded from participation if clinical interview revealed
significant psychological problems (including depression), medical disorders, a history
of head trauma, or if they reported unremitting head pain characterized as diffuse,
bandlike, or a dull ache.
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Non-Headache Control Subjects

An additional eight individuals who were headache free and of similar age to
the headache subjects were recruited as controls. Their participation was limited to
a single session of psychophysiologic monitoring.
All subjects signed an informed consent form prior to participation in the
study, a copy of which appears in Appendix A. A copy of the Human Subjects
Institutional Review Board Human Subjects Approval Form is contained in Appendix
B.

Setting and Apparatus

All sessions were conducted in a sound-attenuated and temperature-regulated
(approximately 73 degrees Fahrenheit) room, in a private clinic setting. Subjects sat
in an overstuffed chair that was reclined at a 45 degree angle, with the experimenter
seated outside the subject's field of vision.
A Med Associates (East Fairfield, VT) modular system was used to monitor
BVP activity, heart rate, and frontalis EMG. BVP activity was monitored with an
AN L-420 reflectance photoplethysmograph.

The transducer was attached with a

Beckman (Houston, TX) double-adhesive collar over the main ramification of the
zygomaticofacial branch of the superficial temporal artery on the side of the head
most frequently associated with headache onset.

The precision in transducer

placement required to obtain a stable waveform with a clear dicrotic notch was aided
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by monitoring the BVP signal on an LBO-508 oscilloscope. For data acquisition, the
BVP signal was processed through a dual following integrator (Model ANL-610,
TC=0.1), an analog to digital converter (Model ANL-944, full wave rectification), and
a D IG -600 interface module, to a laboratory computer for online processing and
storage.

To obtain individual BVP amplitudes, the digitized BVP signal was

processed through a count-to-voltage converter (ANL-945), with the logic "1" output
of the ANL-420's one-shot used to trigger the reset with each pulse wave. The
output of the ANL-945 was routed to a DIG-810 digital display, from which the
individual amplitudes were manually recorded. Heart rate was calculated from the
rate of the BVP waves by the computer.
Frontalis EMG was monitored with Beckman silver/silver chloride electrodes,
with Beckman electrolyte, attached to the skin with adhesive collars 2.5 cm above the
eyebrows. Electrode resistance was kept below 5,000 ohms by preparing the skin
with Bravisol and alcohol. The EMG signal was processed through an amplifier
(ANL-100), EMG coupler and integrator (ANL-140, bandpass = 90-1,000 hertz,
TC=0.1), through an analog to digital converter (ANL-944) and D IG -600 interface
module, to the computer.
For biofeedback training, the output of the count-to-voltage converter (ANL945) was fed through a scaling amplifier (ANL-136) to a LED column display visual
feedback device (ANL-930), and through a voltage controlled oscillator and audio
amplifier (ANL-910) to a shelf speaker. This configuration produced a light column
that changed in height and a tone that changed in tone frequency and volume in an
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analogue stepwise fashion with each cardiac cycle, according to the height of each
BVP amplitude, providing the subject with beat-to-beat feedback of BVP amplitude
changes and variability.
The false (placebo) biofeedback signal was created by routing the logic "1"
output of the A NL-420 to a count-to-voltage converter (ANL-945), with the output
of a time base (DIG-210), through a scaling amplifier (ANL-136), to the feedback
devices identified above. The placebo feedback signal was the product of two factors:
the subject's pulse rate, with which the signal varied inversely (increased pulse
rate/decreased inter-pulse interval produced decreased light column height and
decreased tone frequency and volume) and the superimposed signal manipulation of
the scaling amplifier by the experimenter. The false feedback signal produced by this
configuration appeared identical to the actual BVP biofeedback signal. The fact that
the false feedback was subject to movement artifact (i.e., when a subject might cough
or "test" the signal via movement) in the same way as the actual BVP biofeedback
signal helped make it very credible to the subjects, a problem which exists with using
completely random or non-contingent feedback (Burnette & Adams, 1987).

Experimental Design

This study employed both a within-subject repeated measures ABA reversal
design, with each subject serving as his/her own control, and a randomized group
design, with half of the eight headache subjects randomly assigned to actual BVP
biofeedback training, and the other half receiving false biofeedback. Additionally,
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eight non-headache subjects served as an additional control group for a measure of
BVP variability.

Procedure

All experimental subjects kept a daily headache diary during the five week
Pre-Treatment Baseline Phase and the five week Post-Treatment Phase. Subjects
were provided with data collection forms (Bakal & Kaganov, 1976) on which they
recorded headache intensity 10 times per day, using a 6 point scale (Blanchard,
Theobald, Williamson, Silver, & Brown, 1978), ranging from 0 (no headache) to 5
(severe, incapacitating headache), and recorded all medication taken.
All subjects attended an orientation session which served the dual purpose of
familiarizing them with the biofeedback equipment and for instituting a procedure
designed to minimize BVP measurement artifact in subsequent sessions. As noted
above, pilot investigation had revealed that providing subjects with standard
instructions to lie quietly was, in some cases, insufficient to prevent learned mediation
of the BVP biofeedback signal via frontalis muscle movement. What had initially
appeared to be learned BVP amplitude reduction was, in fact, systematic BVP signal
error caused by photoplethysmograph transducer displacement associated with withinsession EMG trending. Therefore, to minimize EM G-mediated BVP signal error
during the study, subjects were attached to the biofeedback monitors and allowed to
explore the effects of facial muscle movement on the BVP signal, and briefly
instructed in the maintenance of "steady-state" EMG. Additionally, the experimenter
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monitored frontalis EMG during all sessions, and verbally prompted subjects to relax
if frontalis EMG was elevated during transducer hookup, or if within-session EMG
trending occurred of sufficient magnitude to distort the BVP signal.
Subjects attended four pretreatment baseline monitoring sessions, two per
week, during the last two weeks of the Pre-Treatment Baseline Phase. They were
instructed to arrive at the clinic at least ten minutes early to allow for physiological
stabilization. To minimize recording artifact, at the beginning of each session subjects
were reminded to lie as quietly as possible and to avoid irregular respiration. Once
the transducers were attached to the subject, 10 minutes were allowed for adaptation
prior to initiating data collection. At the beginning of data collection, subjects were
instructed to simply sit quietly. Physiological recording lasted for 36 minutes, the
first 4.8 minutes of which constituted the Session Baseline.
Upon completion of the five week Pre-Treatment Baseline Phase, subjects
were randomly assigned to one of two treatment groups (four per group): the BVP
biofeedback training group, or the False Feedback group. Subjects in each group
underwent 12 sessions of their respective type of biofeedback training (actual BVP
feedback versus False Feedback), twice a week for six weeks. As during sessions in
the Pre-Treatment Baseline Phase, physiological recording in the Treatment Phase
sessions lasted for 36 minutes, the first 4.8 minutes constituting the Session Baseline,
the last 31.2 minutes biofeedback training.
Prior to the beginning of the Treatment Phase, all subjects received the same
treatment rationale, which emphasized the role of vasomotor and autonomic instability
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in migraine onset, and the prophylactic value of cultivating awareness and regulation
of their vasomotor activity. The biofeedback signals were explained in terms of BVP
activity to both groups of subjects in a standardized fashion, and they were instructed
to adopt an experimental approach to discovering techniques to "stabilize and
decrease" the light column and tone via imagery, thoughts, or feelings. At every
session, subjects were encouraged to be aware of and regulate their physiology
throughout their daily activities.
For subjects in the False Feedback condition, the false feedback signal, as
noted above, was controlled in part by the experimenter through superimposed
manipulation via a scaling amplifier.

The signal manipulation was patterned to

produce a sense of at least moderate training success for each subject, with the "BVP
signal" appearing to gradually decrease 20-50% within each session.
Following completion of the biofeedback training Treatment Phase, subjects
returned to the laboratory for three monitoring sessions during the Post-Treatment
Phase, once per week for three weeks. Sessions were conducted in the same manner
as those in the Pre-Treatment Baseline Phase.
The eight non-headache control subjects participated in one session during
which their temporal BVP activity was briefly sampled under conditions designed to
be identical to those under which comparable data was sampled from the headache
subjects. The BVP activity was sampled following an orientation to the equipment,
and following a 10 minute adaptation phase and a 4.8 minute Session Baseline.
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Data Reduction

For each session, the computer generated averages for each of 15 2.4 minute
epochs (2.4 minutes x 15 = 36 minutes) for temporal BVP amplitude, heart rate, and
frontalis EMG for each headache subject. The first 4.8 minutes of each session
constituted the Session Baseline.
For computation of BVP variability for all 19 sessions, the final 16 BVP
amplitudes of each Session Baseline and of each session were recorded. Analyses of
changes in BVP amplitude are confined to within-session percent changes from
Session Baselines.

Across-session analyses of temporal BVP zunplitudes are

unreliable because the BVP signal is a relative measure of blood flow, and is
significantly affected by the minute changes in transducer placement across sessions
(Stem, Ray, & Davis, 1980).

Dependent Variables

Self-Report Measures

The Headache Index, adapted from Blanchard et al. (1978) represents the
average daily headache activity (theoretical range = 0 to 50), and is a product of
headache intensity and duration scores recorded on the headache diary forms. It was
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calculated for each phase by summing all intensity scores of the phase and dividing
by the number of days recorded (35).

Medication Index

The Medication Index is a measure of average daily intake that is sensitive to
both the dosage and the relative potency of medications consumed. It was calculated
by first assigning each medication a relative potency value of 1 to 7 based on a scale
developed by the Menninger group (Coyne, Sargent, Segerson, & Osbourn, 1976) and
extended by Blanchard and Andrasik (1985). Each medication's potency value was
then multiplied by the number of doses taken, and the product was divided by 35 to
yield the within-phase daily average.
At the end of the study, percent improvement scores were calculated for each
subject for both headache activity and medication intake using the following formula:

Percent
Improvement = Pre-Treatment Index - Post-Treatment Index x 100
Pre-Treatment Index

Treatment Credibility

To assess treatment credibility and expectation for improvement, subjects were
administered a questionnaire developed by Borkovec and Nau (1972) and modified
by Gauthier, Bois, Allaire, and Drolet (1981) (range = 0-28, higher scores reflecting
higher perceived credibility) at the end of sessions 5, 10, and 19.
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Attribution of Improvement

Subjects were interviewed upon completion of treatment to assess their
perceptions as to why their headaches decreased.

Psychophysiological Measures

BVP Amplitude

The maximum within-session percent decrease in BVP amplitude was
calculated for every session using the following formula: Session Baseline amplitude
(4.8 minute epoch) - lowest session amplitude (2.4 minute epoch) / Session Baseline
amplitude.

Rate of BVP Amplitude Change

Acceleration of the rale of the within-session decreases in BVP amplitude
would be expected to follow the introduction of BVP biofeedback if subjects indeed
learned self-regulation of the BVP signal. Rate of change, as defined by the time
interval from Session Baseline to maximum within-session decrease in BVP
amplitude, was calculated for all Pre-Treatment Baseline Phase sessions and
Treatment Phase sessions.
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BVP Variability

Each subject's BVP amplitude beat-to-beat variability was calculated twice
for each session, using the final 16 BVP amplitudes of each Session Baseline and
each session, and was expressed as the coefficient of variation (CV), which is the
ratio of the SD/X. Thus, the CV is calculated by dividing the standard deviation of
the BVP amplitudes by their mean value. The CV was used to measure changes in
variability because unlike other such measures, the CV is unaffected by differing
mean levels associated with changes in the "gain" or sensitivity settings of recording
equipment (Burdick, 1972).

The maximum within-session percent decrease in heart rate was calculated for
each session using the following formula; Session Baseline heart rate (4.8 minute
epoch) - lowest session heart rate (2.4 minute epoch) / Session Baseline heart rate.
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RESULTS

Credibility Data

Treatment credibility was rated high by both groups. Of a possible maximum
score of 28, the BVP group means at sessions 5, 10, and 19 were 23.5 (range = 2225), 24.5 (range = 23-26), and 23 (range = 22-28). Means for the False Feedback
group were 24.75 (range = 22-28), 25.35 (range = 23-28), and 24.5 (range = 21-28).
A Mann-Whitney U test revealed equivalent treatment credibility across treatment
groups on all three occasions.

Further analysis by Friedman two-way ANOVA

revealed credibility to be statistically unchanged over the course of the study for both
treatment groups.

BVP Data

BVP Amplitude

Maximum within-session percent decreases of BVP amplitudes from Session
Baselines by session and by subject are displayed in Figure 1 and Figure 2 for BVP
and False Feedback treatment groups respectively. Inspection of Figures 1 and 2
reveals within-session decreases ranging from 19% (Subject 8) to 61% (Subject 3)
during Pre-Treatment Phase sessions, with significant w ithin- and between-subject
variability. Notably, for all subjects, the magnitude of within-session decreases in
17
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BVP amplitude observed during Pre-Treatment Phase sessions appears unaffected by
the introduction of biofeedback.
Table 1 displays group averages of maximum within-session percent decrease
of BVP amplitude by experimental phase. Examination of Table 1 fails to reveal
significant differences in average maximum session BVP amplitude decrease across
experimental phases or across treatment groups. In sum, analyses of both withinsubject data and group comparison data fail to show evidence of learned regulation
of BVP amplitude by any subject.

Table 1
Group Averages of Maximum Within-Session Percent Decrease
of BVP Amplitude by Experimental Phase
Pre-Treatment
Baseline
(4 Sessions)

Biofeedback
(12 Sessions)

Post-Treatment
Baseline
(3 Sessions)

BVP (n = 4)

8.8%

18.3%

14.9%

False FB (n = 4)

19.0%

22.0%

19.9%

Group

Rate of BVP Amplitude Decrease

During Pre-Treatment Phase sessions, mean time to maximum within-session
BVP amplitude decrease was 24 minutes for the BVP group and 25 minutes for the
False Feedback group. During Treatment Phase biofeedback sessions, mean time to
maximum within-session BVP amplitude decrease was virtually unchanged for both
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groups, 23 minutes for the BVP group and 24 minutes for the False Feedback group.
Thus, the introduction of BVP biofeedback was not associated with acceleration of the
rate of within-session decrease of BVP amplitude.

BVP Variability

Session baseline and end of session BVP amplitude CVs for each subject and
session are plotted in Figures 3 and 4 for the BVP group and the False Feedback
group respectively. Inspection of Figures 3 and 4 reveals considerable w ithin- and
across-subject and w ithin- and across-session variability of the CV. Visual analysis
of Figure 3 fails to reveal any evidence that subjects learned to decrease BVP
amplitude variability either within or across sessions with the aid of BVP biofeedback.

Clinical Outcome Data

Pre-Treatment Data

Table 2 displays headache and medication index scores and their percent
change for each subject.

Group comparisons at pre-treatment using t tests for

independent means revealed that the BVP and False Feedback groups were equivalent
in terms of the headache and medication indices.
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Table 2
Headache and Medication Index Scores Pre- and Post-Treatment
and Their Percent Change Scores for Individual Subjects
Subjects by Group

Headache Index
Pre

Post

% Change

Medication Index
Pre

Post

% Change

BVP
1
2
4
7

10.2
5.7
12.8
5.8

7.3
0.2
6.7
1.2

-28.8%
-96.0%
-47.3%
-78.8%

3.4
2.7
9.1
2.7

1.8
0.2
4.5
0.3

-46.7%
-93.6%
-50.2%
-88.5%

False Feedback
3
5
6
8

19.8
5.9
25.4
6.5

1.9
3.0
14.8
2.0

-90.5%
-50.0%
-41.6%
-68.9%

5.7
1.4
3.1
4.9

0.3
0.5
1.9
1.4

-95.0%
-65.3%
-39.8%
-71.5%

Treatment Effects

Mean reductions in headache activity were virtually identical across groups at
60% and 62% for the BVP and False Feedback groups respectively. Paired t tests
revealed significant reductions in headache activity for the BVP group (1(3) = 7.01,
p=<.01) and the False Feedback group (1(3) = 2.63, p=<.05) using one-tailed
probabilities. Mean reduction in medication intake was also similar across groups at
62% and 73% for the BVP and False Feedback groups respectively. The statistical
significance of medication reductions was confirmed for both the BVP group (1(3) =
4.43, p=<.05) and the False Feedback group (1(3) = 2.59, p=<.05).
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To assess whether the magnitude of improvements were equivalent across
groups, t tests for independent means were applied to post-treatm ent headache and
medication indices and to their percent change scores. No significant differences were
revealed.
To assess the clinical significance of these improvements, subjects were
classified as successful if they attained at least a 50% reduction in headache activity.
Inspection of Table 2 shows five of the eight subjects to be treatment successes (63%
of all subjects), three of the five successes belonging to the False Feedback group.
In regard to medication intake, 6 of the 8 subjects (75% of all subjects) reported at
least a 50% reduction.

Correlations Between Credibility Ratings
and Treatment Outcome

The relationship between perceived treatment credibility £md treatment outcome
was assessed via Spearman-rank correlation coefficients.

Correlations were not

significant at sessions one and six. However, a significant association developed by
post-treatment (rs = .88, p=<.01), the subjects who were most improved reporting
treatment as most credible.

Correlations Between BVP Amplitude Reductions
and Treatment Outcome

To assess whether treatment outcome was related to within-session BVP
amplitude reduction, Spearman-rank correlations were calculated between headache
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change percentage scores and the number of sessions in which BVP amplitude
decreased by various levels. None of the correlations was statistically significant.

Correlations Between BVP Variability
and Treatment Outcome

To assess whether treatment outcome was related to BVP beat-to-beat
variability, Spearman-rank correlations were calculated between headache percentage
change scores and CVs at session baseline and at session end averaged for each
treatment phase. None of the correlations was significant.

BVP Variability of Headache Subjects
Versus Non-Headache Controls

To determine whether the temporal BVP amplitude variability of headache
subjects was greater than that of non-headache controls when sampled under similar
conditions (during the Session Baseline of the initial session), the group mean CV of
the 8 headache subjects was compared to the mean CV of the 8 non-headache
controls (12.8 and 7.8 respectively). A Mann-Whitney U test revealed a significant
group mean difference at the .05 level (U(l,16) = 8, p<.05).

W ithin-Subject Correlations Between Decreases
in BVP and Heart Rate

The average within-session reduction in heart rate for all subjects was -5.3%
during pre-treatment baseline sessions, and -6.4% during feedback sessions. To
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assess the extent to which an individual subject's reductions in BVP amplitude were
associated with reductions in heart rate, Pearson product-moment correlations were
calculated between each session's maximum percent reduction in BVP amplitude and
the corresponding percent reduction in heart rate. Correlations were significant for
three of the eight subjects: Subject 1 (i = .69, p<.02). Subject 2 (i = .72, p<.01), and
Subject 6 (r = .84, p<.01), and approached significance for Subject 5 (i = .51, p =
.07).

Attribution of Improvement

Following treatment, subjects were interviewed to assess what they attributed
their improvement to. Several themes were identified in the responses of all eight
subjects:
1.

The learning and practicing of relaxation skills (subjects generally

perceived biofeedback training as an aid towards cultivating relaxation).
2. An increased awareness and regulation of pre-headache states (in terms of
physiological sensations and emotions).
3. Dietary changes (i.e., avoiding caffeine, eating a healthier diet, not skipping
meals).
4.

Cognitive changes (i.e., "seeing" self as more competent, feeling more

confident, "perceiving stressful situations differently").
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DISCUSSION

The present data confirm that migrainuers exhibit greater beat-to-beat
variability of temporal artery BVP amplitudes under baseline conditions compared to
non-headache controls, a finding consistent with previous reports (Graham & Wolff,
1938; Morley, 1985; Tunis & Wolff, 1953). However, migrainuers were not able to
learn to decrease beat-to-beat BVP amplitude variability with the aid of biofeedback
training. Furthermore, there was no correlation between the degree of headache relief
and the amount of BVP amplitude variability. Thus, the data suggest that learned
self-regulation of BVP amplitude variability is neither a necessary or even an
attainable therapeutic goal in the treatment of migraine.
While within-session reductions of temporal artery BVP amplitude were
observed during biofeedback training, these reductions appear to be a result of
adaptation to the experimental situation rather than biofeedback training. Specifically,
all subjects showed significant within-session reductions in BVP amplitude during the
four pre-treatment baseline monitoring sessions, and the introduction of BVP
biofeedback training failed to increase the magnitude or the rate of these reductions.
Furthermore, subjects undergoing False Feedback showed reductions in BVP
amplitude comparable to those shown by subjects undergoing BVP biofeedback.
Thus, there was no evidence that the reductions in BVP amplitude which occurred

28

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

29
during biofeedback training were the result of learned control of the BVP feedback
signal or self-regulation of temporal artery BVP amplitude.
The data confirm that undergoing BVP biofeedback training is followed by
significant reductions in headache activity and medication intake. However, equally
significant reductions were reported by subjects who underwent the equally credible
False Feedback placebo procedure. Further, the degree of headache relief was not
correlated with the magnitude of BVP amplitude reduction or with the amount of p reor post-treatment BVP variability. Thus, the data do not support a specific treatment
effect of BVP biofeedback.
Regarding the mechanisms by which the BVP biofeedback and the False
Feedback procedures resulted in significant clinical improvement, the present data
provide some support for lowered physiological arousal, or what has been termed the
"conditioned adaptation-relaxation reflex" (Dalessio et al., 1979; Sovak et al., 1978)
as a mediator of treatment success. Relaxation is associated with a general decrease
in sympathetic tonic outflow, and characterized by reduced blood flow to the head,
dilation of peripheral arteries, and decreased heart rate. The results of the majority
of well-controlled investigations indicate that relaxation training, with or without the
aid of biofeedback, is effective in the treatment of migraine, and that for most
migrainuers, treatment efficacy is unchanged by the addition of biofeedback
(Chapman, 1986).

In the present study, all subjects showed evidence of general

relaxation through decreased heart rate and temporal artery BVP amplitude.
Additionally, a strong correlation between the magnitude of reductions in heart rate
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and BVP amplitude were shown by half of the subjects. However, no significant
correlation was found between the magnitude of reductions in BVP and headache,
which could theoretically be present but undetected due to a small subject pool and
considerable variability of the responses involved.
An alternative explanation for headache reduction following biofeedback
training is that the regulation or lowering of physiological arousal, as measured by
psychophysiological parameters, is but one of several mechanisms which operate in
the context of biofeedback training.

As noted by Chapman (1986), the ritual of

biofeedback training is exceedingly complex, and whatever association that may exist
between headache parameters and physiological parameters, it is not simple.
Biofeedback is increasingly being conceptualized as a process which alters cognitive,
emotional, biochemical, and behavioral responses. In reviewing the medical literature,
Raskin (1988) noted a growing consensus that migraine is a manifestation of a
lowered biological threshold to a wide variety of internal and external stimuli, that
instability of serotonergic neurotransmission (centrally and peripherally) is an
important pathogenic mechanism, and that associated vascular and muscular changes
are probably epiphenomena. This model of migraine suggests that a mechanism or
"final common pathway" of various behavioral (and medical) interventions in treating
migraine is via the prevention of the dysregulation of serotonergic neurotransmission,
to which migrainuers appear to be inherently susceptible (Raskin, 1988).

Thus,

regulation of physiological arousal through the practice of learned relaxation skills,
the alleviation of emotional distress, avoiding caffeine, alcohol, and other dietary
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triggers, and regularity of eating and sleeping may all potentially serve to prevent the
dysregulation of serotonergic neurotransmission in the migrainuer. Indeed, in the
present study, all subjects reported increased awareness and regulation of emotional
and physiological arousal, avoidance of caffeine and sugar, increased regularity of
eating, and an altered perception of self and others in which they felt more control,
even though the experimenter provided no instruction in these matters. It appeared
that during the course of biofeedback training (false or otherwise), subjects were
stimulated by their biofeedback experience (including perhaps their perceived success)
to act on previously acquired information regarding headache prevention and
management. This is consistent with the model of therapeutic change in biofeedback
training which emphasizes mediating cognitive factors which include enhanced selfefficacy and internal locus of control, leading to altered coping behaviors (Bandura,
1977; Frank, 1976; Holroyd et al., 1984). Holroyd et al. (1984) reported that changes
in self-efficacy and locus of control correlated with tension headache reduction in
subjects undergoing EMG biofeedback, while EMG activity was uncorrelated with
treatment outcome.

Future investigations designed to assess the mechanism of

biofeedback's effectiveness in treating migraine should assess changes in diet, sleep,
exercise, emotional arousal, interpersonal relationships, cognitive factors, and
perceived success at biofeedback training, all of which may be affected by the
biofeedback training ritual, whether or not they are explicit intervention targets. For
example, in a recent study the majority of migrainuers reported a reduction of at least
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50% in headache frequency after receiving brief instruction on the identification and
avoidance of headache triggers (Biau & Thavapalan, 1988).
The present data underscore the importance of assessing for the effects of
adaptation before attributing physiological changes to BVP biofeedback training, and
raises questions about prior research in which adaptation was not assessed. Further,
based on clinical outcomes, the present data fail to justify the additional expense and
time required to utilize BVP biofeedback training in migraine treatment.
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INFORMED CONSENT

I ) _________________
, w illin g ly a g ree to p a rticip a te in th is resea rch
stu d y w hich has b een exp lain ed to me to my sa tisfa c tio n . This s tu d y is
being co n d u cted a t Health P sy ch o lo g y , P.C.
This s tu d y has b een d esig n ed to in v e stig a te th e e f f e c t s o f b iofeed b ack
train in g on m igraine h ead ach e sym ptom ology and a v a r ie ty o f body
fu n ctio n s in clu d in g m uscle te n sio n , h eart ra te, sk in tem p eratu re, and
vasom otor a c tiv ity (co n strictio n and dilation o f blood v e s s e ls ).
By e lectin g to p articip a te in th is s tu d y I w ill be c o n se n tin g to 1) daily
record h eadache sym ptom ology and m edication in ta k e, 2) com plete a
q u estio n n a ire on m edical an d h eadache h isto r y , 3) com plete a
q u estio n n a ire on d e p r e ssio n sym ptom ology, 4) refr a in from tak in g v a so 
active m edications d u rin g th e s tu d y , and 5) u n d erg o approxim ately 20
b iofeed b ack tra in in g /m o n ito rin g s e s sio n s of 40-60 m inutes duration
sch ed u led o v er a 5-6 month p erio d . I u n d ersta n d th a t su rfa ce se n so r s
will be a tta ch ed to my hand, fo reh ea d , and tem ple.
I u n d ersta n d th a t b y th e p r o c e s s o f random (ch a n ce) selec tio n , I will be
a ssig n e d to r e c e iv e one o f two ty p e s o f b iofeed b ack , one o f w hich may not
be as e ffe c tiv e as th e o th er ty p e . I u n d ersta n d th e r e is no gu aran tee
th at th e b iofeed b ack tra in in g I r e c e iv e will r e s u lt in a red u ctio n in my
headache pain.
I u n d ersta n d th at th ere are v ir tu a lly no r isk s in v o lv e d in b iofeed b ack
train ing. It has b een exp lained to me th at th e b io feed b a ck u sed in th is
stu d y is c o n str u c te d with b u ilt-in e le c tr o n ic /o p tic a l iso la tio n to p ro tect
me from re c e iv in g e lectric a l sh o ck in th e e v en t o f eq uipm ent fa ilu re, local
power problem s, etc.
It has been exp lained to me th a t I may b en efit from p articip ation in th is
stu d y b y ga in in g se lf-a w a r e n e s s o f headache tr ig g e r s , and p o ssib le
d ecrea sed m edication in ta k e a n d /o r headache sym ptom ology.
I
u n d ersta n d th at my p articip a tio n may be of valu e in a d v a n cin g scien tific
know ledge w ith r e s p e c t to th e e f f e c t s o f b iofeed b ack tra in in g on migraine
headache sym ptom ology and p h y sio lo g y .
I u n d ersta n d th at
stu d y w ill be held
r esu ltin g from my
other id e n tify in g
anonym ity.

th e inform ation ob tain ed from my p articip ation in th is
co n fid en tia l. I u n d ersta n d th a t in th e e v e n t th a t data
p articip ation are u sed a p u b lication , my name or any
inform ation will not be relea sed so as to p ro tect my

I u n d ersta n d th a t my p a rticip a tio n is en tir e ly v o lu n ta ry .
I also
u n d ersta n d th a t I may w ithdraw from the s tu d y at any time.
I
u n d erstan d th at I may ask q u e stio n s co n cern in g my p articip ation during
th e co u rse of the stu d y .
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I u n d ersta n d th at it is u n lik e ly th a t p h y sica l or p sy ch o lo g ica l in ju r y w ill
r e s u lt from th e s e r e se a r c h p ro ced u res. In the e v e n t of untow ard sid e
e ffe c ts how ever, ca re w ill b e a rra n g ed b u t not paid fo r b y th e P rin cip al
In v estig a to r or W estern M ichigan U n iv ersity .
I h ave read th e Inform ed C o n sen t, h ave had my q u e stio n s a n sw ered to my
sa tisfa ctio n b y th e P rin cip al In v e stig a to r , and fr e e ly a g ree to p a rticip a te.

(sig n a tu re of p a rticip a n t)

(w itn ess)

(date)

(date)

I u n d ersta n d th a t if I h a v e a n y com plaints a fter g iv in g c o n s e n t, I may
co n ta ct the P rincipal I n v e stig a to r a n d /o r th e Human S u b je c ts Review
Board of W estern M ichigan U n iv e r sity . I u n d ersta n d th a t I may co n ta ct
th e Human S u b je cts R eview Board w ith ou t going th ro u g h th e P rincipal
In v estig a to r.
Principal In v estig a to r: Paul G reilick, M.A.
Limited L icen sed P sy ch o lo g ist
Health P sy c h o lo g y , P.C.
375-0624
Human S u b jects Review
Board Chair:
Mike P ritch ard , Ph.D.
D epartm ent of P hilosop h y
W estern M ichigan U n iv ersity
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